Cancer treatment with hormone therapy and its relationship with xerostomia and hyposalivation


  • Gláucia Helena Faraco de Medeiros
  • Jheiniffer Folchinhi
  • Daniela Daufenback Pompeo
  • Jefferson Ricardo Pereira



breast neoplasms; women; xerostomia; hyposalivation antineoplastic agents.


The appearance of new drugs for cancer treatment has increased patient survival but it has also brought adverse effects, such as the sensation of dry mouth and hyposalivation Objective: To assess the relationship of using hormone therapy in breast and prostate cancer patients and the occurrence of xerostomia and hyposalivation. Material and methods: Cross-sectional study with 114 patients diagnosed with cancer and treated with hormone therapy. The researcher collected resting and stimulated salivary flows in the morning. The descriptive statistic analysis, chi-square test (p<0.005), and t-test (><0.005), and t-test (<0.005) were performed using the Statistical Package for Social Science™ (SSPS), version 21, for different variables of hyposalivation and hormone therapy. Results: The results showed that 67 (55.8%) patients using hormone therapy drugs presented hyposalivation and 73 (64%) patients presented xerostomia. a. Conclusion: According to the results of this study, there is a positive association between stimulated hyposalivation and the use of hormone therapy drugs (p = 0.015). There was also a positive association between hyposalivation and xerostomia and the use of hormone therapy drugs (p = 0.049 and p = 0.001).




Como Citar

Gláucia Helena Faraco de Medeiros, Jheiniffer Folchinhi, Daniela Daufenback Pompeo, & Jefferson Ricardo Pereira. (2023). Cancer treatment with hormone therapy and its relationship with xerostomia and hyposalivation. RSBO, 20(1), 25–30.



Original Research Article